Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

CATALYST investigators

科研成果: 期刊稿件文章同行评审

41 引用 (Scopus)
源语言英语
页(从-至)255-266
页数12
期刊The Lancet Respiratory Medicine
10
3
DOI
出版状态已出版 - 3月 2022
已对外发布

!!!ASJC Scopus Subject Areas

  • 肺和呼吸道医学

指纹

探究 'Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial' 的科研主题。它们共同构成独一无二的指纹。

引用此